CVAC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

13.35M

-7.93%

-0.090

-35.71%

0.00

-100%

0.000

-100%

0.00

-100%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for CureVac N.V. (CVAC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -13.38%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-13.38%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for CureVac NV (CVAC.O) is -7.85, compared to its 5-year average forward P/E of -10.61. For a more detailed relative valuation and DCF analysis to assess CureVac NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.61

Current PE

-7.85

Overvalued PE

-0.24

Undervalued PE

-20.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.26

Current EV/EBITDA

-4.64

Overvalued EV/EBITDA

2.59

Undervalued EV/EBITDA

-23.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

29.92

Current PS

10.97

Overvalued PS

71.83

Undervalued PS

-11.98

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CVAC News & Events

Events Timeline

No data

News

7.0

2025-12-22Benzinga

Honeywell Lowers FY2025 EPS Guidance to $9.70-$9.80 Amid Business Unit Discontinuation

8.5

2025-12-22Benzinga

Clearwater Analytics (CWAN) Acquired by Private Equity Consortium for $8.4 Billion

8.5

2025-12-18Globenewswire

BioNTech Completes CureVac Acquisition with 86.75% Shares Tendered

People Also Watch

Frequently Asked Questions

What is CureVac NV (CVAC) stock price today?

The current price of CVAC is 0 USD — it has decreased -0.21 % in the last trading day.

What is CureVac NV (CVAC)'s business?

CureVac CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

What is the price predicton of CVAC Stock?

Wall Street analysts forecast CVAC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVAC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is CureVac NV (CVAC)'s revenue for the last quarter?

CureVac NV revenue for the last quarter amounts to 54.13M USD, decreased -89.04 % YoY.

What is CureVac NV (CVAC)'s earnings per share (EPS) for the last quarter?

CureVac NV. EPS for the last quarter amounts to 1.21 USD, decreased -19.33 % YoY.

What changes have occurred in the market's expectations for CureVac NV (CVAC)'s fundamentals?

How many employees does CureVac NV (CVAC). have?

CureVac NV (CVAC) has 825 emplpoyees as of January 10 2026.

What is CureVac NV (CVAC) market cap?

Today CVAC has the market capitalization of 753.67M USD.